ClinicalTrials.gg
RecruitingNCT07052175PreCareUpdated May 14, 2026

Prevention of Relapse in Behavioral Disorders

An interventional study of Standard Multidisciplinary Treatment and Digital Monitoring Tool in Substance-related Disorders, sponsored by Clínica Nuestra Señora de la Paz. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Clínica Nuestra Señora de la Paz · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Substance-Related Disorders with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Spain.

Planned enrollment
8th of 20
150 · median 131
Started
2026
with 1 other
No phase
17 of 26
4 open now
Registered
25th of 26
by date
Lead sponsor
1 of 26
Clínica Nuestra Señora de la Paz

Among the 26 studies in Substance-Related Disorders with a site in Spain, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, and was the 25th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 26 studies in Substance-Related Disorders with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Substance-Related Disorders with a site in Spain, or all of them as a file.
02

Study summary

This study aims to validate the effectiveness of a digital tool for monitoring and early relapse detection in addiction treatment. It compares outcomes between a traditional multidisciplinary model and the same model enhanced by the technology. The research seeks to demonstrate the tool's added clinical value in improving long-term recovery outcomes.

Read the detailed description

The primary objective of this research project is to scientifically validate the effectiveness of a technological tool for monitoring and early detection of relapse in addiction treatment. The study will focus on comparing two approaches: the traditional comprehensive multidisciplinary treatment model and the same model enhanced by the integration of a digital technology.

The comprehensive model addresses the biological, psychological, and social dimensions of substance use disorders through a structured sequence of phases: initial assessment, detoxification, withdrawal management, rehabilitation, social reintegration, and follow-up care. The core innovation of this study lies in the implementation of a digital application specifically designed to monitor patients' clinical status, detect early warning signs of relapse, and deliver timely, personalized interventions.

A longitudinal quasi-experimental study will be conducted with a sample of 150 individuals diagnosed with substance use disorders (including alcohol, cocaine, and other stimulants). Validated assessment instruments will be used to evaluate clinical progress, comparing outcomes between patients receiving standard treatment and those receiving the same treatment augmented by the digital tool.

Key outcome variables include reduction in withdrawal symptoms, decrease in craving, improvement in emotional well-being and psychosocial functioning, relapse rates, and patient satisfaction. In addition, the feasibility, acceptability, and clinical utility of the technological tool in therapeutic follow-up will be assessed.

The study is expected to provide empirical evidence on the added value of the digital tool in addiction treatment, with the aim of optimizing existing clinical protocols and enhancing the long-term effectiveness of intervention strategies.

03

Conditions studied

  • Substance-related Disorders

Keywords

  • Substance use disorders
  • relapse prevention
  • multidisciplinary treatment
  • digital health
  • monitoring
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand spoken and written Spanish.
  • Signing the .
  • Own a smartphone with internet access and an iOS or Android operating system.

Exclusion criteria

Exclusion Criteria:

  • Institutionalized or incarcerated patients, or those anticipating imminent incarceration, without regular access to mobile phone use.
  • Refusal to install the mobile application.
  • Inability to understand and sign the form for any reason.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Standard Treatment Group

    Participants in this group will receive the standard multidisciplinary treatment for substance use disorders, including clinical evaluation, medical detoxification, psychological and psychiatric therapy, occupational rehabilitation, and social reintegration, without the use of the digital tool

    Behavioral: Standard Multidisciplinary Treatment

  • Experimental
    Digital-Assisted Treatment Group

    Participants in this group will receive the same standard multidisciplinary treatment as Arm 1, complemented by a digital tool designed for real-time monitoring, early relapse detection, and personalized feedback throughout the follow-up phase

    Behavioral: Standard Multidisciplinary Treatment · Behavioral: Digital Monitoring Tool

Interventions

  • BehavioralStandard Multidisciplinary Treatment

    Comprehensive intervention including structured phases: initial assessment, detoxification, withdrawal management, psychological and psychiatric therapy, rehabilitation, and follow-up care. Delivered by a multidisciplinary team according to established clinical protocols.

  • BehavioralDigital Monitoring Tool

    In addition to standard care, participants will use a mobile application that monitors clinical indicators, detects early signs of relapse risk, and provides personalized alerts and intervention prompts. The tool is designed to support both patients and clinicians in decision-making and therapeutic follow-up.

06

What researchers measure

Primary outcomes

  1. Biological Verification of Substance Use Relapse via Toxicological Testing: Urinalysis

    To objectively identify episodes of relapse (e.g., alcohol or other substance use) during treatment, periodic toxicological screenings will be performed as part of the therapeutic monitoring process. These screenings are conducted by clinical personnel and include urinalysis: detection of recent use of psychoactive substances through urine samples, providing an objective measure of treatment adherence.

    Time frame: Throughout the intervention and follow-up phases (baseline to 12 months)

  2. Biological Verification of Substance Use Relapse via Toxicological Testing: Breath Alcohol Testing

    To objectively identify episodes of alcohol relapse during treatment, periodic toxicological screenings will be conducted as part of the therapeutic monitoring process. These screenings will be carried out by clinical staff and will include Breath Alcohol Testing: measurement of breath alcohol concentration using spirometry-based devices to detect recent alcohol consumption.

    Time frame: Throughout the intervention and follow-up phases (baseline to 12 months)

Secondary outcomes

  1. WHOQOL-BREF

    A 26-item instrument assessing perceived quality of life across four domains: physical health, psychological well-being, social relationships, and environmental context. Items are rated on a 5-point Likert scale, and domain scores are transformed to a 0-100 scale. Demonstrates good internal consistency, with Cronbach's alpha ranging from 0.69 (physical) to 0.90 (spirituality/religion/personal beliefs).

    Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)

  2. Purpose in Life Test - Short Form (PIL-10)

    A 10-item self-report scale assessing life purpose and personal meaning, adapted from the original PIL (Crumbaugh \& Maholick, 1969). Responses are rated on a 7-point Likert scale, with total scores ranging from 10 to 70. Higher scores reflect greater perceived purpose. The scale includes two dimensions: (a) life satisfaction and meaning, and (b) goals and direction. Shows good psychometric properties (α = .85 overall; .84 for life satisfaction and .69 for goals and purpose).

    Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)

  3. Patient Health Questionnaire-9 (PHQ-9)

    A 9-item self-report tool assessing depressive symptom severity over the past two weeks, based on DSM-IV criteria. Each item is scored from 0 (not at all) to 3 (nearly every day), yielding a total score of 0-27. A cut-off score of 10 yields sensitivity of 0.78 and specificity of 0.87. Spanish versions show excellent reliability (α = 0.78-0.90), with current data showing α = .93.

    Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)

  4. Beliefs About Substance Use and Craving Beliefs Questionnaire

    25 items self-report questionnaire designed to assess maladaptive beliefs related to substance use and beliefs about substance craving. Each item is rated on a 5-point Likert scale ranging from "totally disagree" to "totally agree". Higher total scores reflect stronger dysfunctional beliefs associated with substance use (e.g., perceived benefits or inevitability of use). The instrument shows excellent internal consistency (Cronbach's alpha = 0.87).

    Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)

Other outcomes

  1. Patient Satisfaction with the Digital Application

    27-item ad hoc questionnaire using a 5-point Likert scale (scale from 1 to 5, with 1 being "Not at all" and 5 being "Very much") to assess patient satisfaction with the application's usability, safety, and overall experience. Higher scores indicate greater satisfaction.

    Time frame: Post-treatment (3 months)

07

Study locations

2 of 2 sites recruiting
  • Centro de San Juan de Dios de Ciempozuelos
    Ciempozuelos, Madrid 28350, Spain
    Recruiting
  • Clínica Nuestra Señora de la Paz
    Madrid, Madrid 28033, Spain
    Recruiting
08

References and documents

Publications

  • Salom R, Pico Rada A, Munoz Garcia JJ, Garcia-Mieres H, Artes-Rodriguez A. Digital relapse prevention plan for substance use disorders: study protocol for a multicentre randomised controlled trial. BMJ Health Care Inform. 2025 Nov 24;32(1):e101808. doi: 10.1136/bmjhci-2025-101808. PubMed 41290251 ↗

Individual participant data

Plan to share: No — IPD information will not be shared due to the sensitivity of the data it contains, which could allow for the direct or indirect identification of patients.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 8 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jul 4, 2025
StartActual
Apr 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07052175
Lead sponsor
Clínica Nuestra Señora de la Paz
Collaborators
Universidad Carlos III de Madrid
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Apr 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 14, 2026

Study contacts

Rafael Salom Borrás, PhD
Contact
rafael.salom@sjd.es
+34 914 15 60 00
Álvaro Pico Rada, Psychiatrist and Medical Direc
Contact
alvaro.pico@sjd.es
+34 914 15 60 00
Juan Jesús Muñoz García, PhD
principal investigator · Centro San Juan de Dios de Ciempozuelos
Antonio Artés, PhD
principal investigator · Department of Signal Theory at Universidad Carlos III
Apolo Zepeda Avilés, Medical Director
principal investigator · Hospital San Juan de Dios de Gipuzkoa
Enrique Bermúdez Navas, Psychiatrist
principal investigator · Centro Asistencial San Juan de Dios Palencia
Placidia Franco Suárez-Bárcena, Technical Director
principal investigator · Centro Asistencial San Juan de Dios Palencia
Rafael Salom Borrás, PhD
principal investigator · Clínica Nuestra Señora de la Paz, Orden Hospitalaria San Juan de Dios, Madrid, Spain
Álvaro Pico Rada, Medical Director
principal investigator · Clínica Nuestra Señora de la Paz, Orden Hospitalaria San Juan de Dios, Madrid, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion